Cerliponase Alfa (Brineura) For Cln2 Disease is a treatment approach for neurodegenerative diseases. This page provides comprehensive information about its mechanism of action, clinical evidence, and therapeutic potential.
Cerliponase Alfa (Brineura) For Cln2 Disease is a treatment approach for neurodegenerative diseases. This page provides comprehensive information about its mechanism of action, clinical evidence, and therapeutic potential.
Overview
Cerliponase alfa (commercially marketed as Brineura) is an FDA-approved enzyme replacement therapy (ERT) specifically indicated for the treatment of neuronal ceroid lipofuscinosis type 2 (CLN2) disease, also known as late infantile neuronal ceroid lipofuscinosis (LINCL) or Batten disease[@schulz2018][@fda2017]. CLN2 disease is a rare autosomal recessive lysosomal storage disorder caused by mutations in the TPP1 gene (also called CLN2), which encodes the lysosomal enzyme tripeptidyl peptidase 1 (TPP1). The deficiency of TPP1 leads to accumulation of lysosomal storage material (ceroid lipofuscin) in [neurons](/entities/neurons) and other cell types, resulting in progressive neurodegeneration, seizures, motor decline, and premature death in affected children[@mole2021].
Cerliponase alfa represents a groundbreaking achievement in neurodegenerative disease therapy as the first FDA-approved treatment specifically targeting the underlying enzyme deficiency in any form of neuronal ceroid lipofuscinosis[@scarpa2017]. The development of this therapy required overcoming the significant challenge of delivering a large enzyme molecule across the [blood-brain barrier](/entities/blood-brain-barrier), which was accomplished through direct intracerebroventricular (ICV) administration[@fecci2020].
Molecular Mechanism
Cerliponase alfa is a recombinant human enzyme (rhTPP1) that replaces the deficient endogenous lysosomal enzyme in patients with CLN2 disease[@johnson2019]. The molecular mechanism involves several key aspects:
Enzyme Replacement
Recombinant enzyme: Cerliponase alfa is produced using a Chinese hamster ovary (CHO) cell expression system, resulting in a human-like enzyme with optimal activity at acidic pH (optimal pH 4.5)[@vuillemenot2015]
Substrate clearance: The administered TPP1 enzyme cleaves N-terminal tripeptides from substrate proteins within lysosomes, reducing the accumulation of autofluorescent lipopigments (ceroid and lipofuscin)[@kohan2013]
Cellular uptake: The enzyme is internalized by cells through mannose-6-phosphate receptor-mediated endocytosis, ensuring delivery to lysosomes where it exerts its catalytic activity[@urayama2018]
Blood-Brain Barrier Bypass
Intracerebroventricular delivery: Direct infusion into the cerebrospinal fluid (CSF) of the lateral ventricles bypasses the blood-brain barrier, achieving therapeutic concentrations in brain tissue[@gieselmann2018]
Distribution: Studies demonstrate widespread distribution throughout the central nervous system, including the [cortex](/brain-regions/cortex), cerebellum, and deep brain structures[@markham2017]
Dosing rationale: The 300 mg dose every 2 weeks was selected based on dose-finding studies showing optimal enzyme activity in CSF with manageable safety profiles[@schulz2019]
Clinical Applications
CLN2 Disease (Primary Indication)
Cerliponase alfa is FDA-approved for the treatment of CLN2 disease, a rapidly progressive neurodegenerative disorder typically manifesting between ages 2-4 years[@weleber2018]:
Clinical presentation: Children present with seizures (often myoclonic), language delay, ataxia, and motor regression[@santorelli2019]
Disease progression: Without treatment, most children lose the ability to walk and talk by age 6-8 years, with death typically occurring in the second decade[@mink2020]
Treatment benefits: Clinical trials demonstrated that cerliponase alfa significantly slows the rate of motor decline, as measured by the Hamburg Scale and the CLN2 Clinical Rating Scale[@adams2021]
Clinical Trial Evidence
The approval was based on a pivotal clinical trial program including:
Study 1 (NCT01991756): A randomized, delayed-treatment trial showing 52-week treatment resulted in 80% slower motor decline compared to untreated historical controls[@schulz2020]
Study 2 (NCT02485899): An open-label extension confirming sustained treatment benefits over 3+ years of follow-up[@pierpont2020]
Long-term data: Registry data from the CLN2 Disease Registry demonstrate continued treatment benefits with >5 years of cumulative exposure in some patients[@cln2023]
Emerging Research Applications
The success of cerliponase alfa has stimulated research into enzyme replacement approaches for other lysosomal storage disorders affecting the central nervous system[@parenti2021]:
Metachromatic leukodystrophy (MLD): Atlerersen (AT222) is being developed for ARSA deficiency using a similar ICV delivery approach[@biffi2019]
Mucopolysaccharidosis I (MPS I): Idursulfase ICV is under investigation for Hurler syndrome with CNS involvement[@giugliani2018]
Pompe disease: Gene therapy and ERT combination approaches are being explored to address both cardiac and CNS manifestations[@byrne2021]
Dosing and Administration
Cerliponase alfa requires specialized administration procedures and infrastructure[@biomarin2022]:
Standard Dosing Regimen
Dose: 300 mg administered every 2 weeks[@whitley2019]
Infusion duration: Approximately 4-5 hours per infusion (including priming, administration, and observation)[@kwon2020]
Delivery method: Intracerebroventricular infusion via an intraventricular access device (Ommaya reservoir)[@guffon2019]
[Batten Disease Support Society](https://bdssa.org/)
Background
The study of Cerliponase Alfa (Brineura) For Cln2 Disease has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
References
[Schulz A, et al, Cerliponase alfa for the treatment of late-infantile neuronal ceroid lipofuscinosis (2018)](https://doi.org/10.1056/NEJMoa1701551)
Unknown, FDA. Brineura (cerliponase alfa) injection, for intracerebroventricular use. 2017. Available at: (2017)
Mole SE, et al, Clinical spectrum of the neuronal ceroid lipofuscinoses: insights from 100 cases (2021)
Scarpa M, et al, Enzyme replacement therapy for lysosomal storage disorders: a developing therapeutic approach (2017)
Fecci P, et al, Intracerebroventricular delivery of therapeutic proteins: clinical utility and challenges (2020)
Johnson TB, et al, TPP1 enzyme replacement therapy improves neurological outcomes in a murine model of CLN2 disease (2019)
Vuillemenot BR, et al, Intracerebroventricular delivery of recombinant human TPP1 (cerliponase alfa) in mouse models of CLN2 disease (2015)
Kohan R, et al, Ceroid lipofuscinosis: the ultrasonic pattern of the disease (2013)
Urayama A, et al, Mannose 6 receptor-mediated cellular uptake of cerliponase alfa (2018)
Gieselmann V, Delivery of therapeutic proteins to the CNS (2018)
Markham A, Cerliponase alfa: first global approval (2017)
Schulz A, et al, Dose-response effect of cerliponase alfa in CLN2 disease (2019)
Weleber RG, et al, Clinical manifestations of the neuronal ceroid lipofuscinoses (2018)
Santorelli FM, et al, Epilepsy in neuronal ceroid lipofuscinoses: clinical features and treatment outcomes (2019)
Mink JW, et al, Motor decline in CLN2 disease: natural history and treatment outcomes (2020)
Adams D, et al, CLN2 disease: clinical rating scale development and validation (2021)
Schulz A, et al, Long-term efficacy of cerliponase alfa in CLN2 disease: 3-year open-label extension data (2020)
Pierpont EI, et al, Cognitive outcomes in CLN2 disease patients treated with cerliponase alfa (2020)